[ Log In ]

Database Information

New website
Wednesday 26 March 2014
Dear TBDReamDB users, as you see the website has recieved a new updated look. It is not only the layout of the website that has changed, the whole database structure is now up to standards with modern relational databases. This will ease your search for the information you are looking for, but also for the management of adding additional data to the database. One new function of TBDReamDB is that the users can submit mutation data to be included in the database. This is a moderated function, so all submitted mutations, need to be approved by an administrator before inclusion in the public database. Up in the right hand side corner of the homepage you can create an account. For normal use, there is no need to register, but if you want to take advantage of the possibility to submit mutation data you are required to register and be approved as a "super user". If you are intereted in becoming a super user and know more about the way to submit mutations, please contact us at curator@tbdreamdb.com TBDReamDB can still be accessed through www.tbdreamdb.com, but we have physically moved the database so it is now housed at Karolinska Institutet in Stockholm Sweden, as you see you have been directed to tbdreamdb.ki.se you can save this as a bookmark to directly go to the website. If you have any questions related to the new functions of the website, or you have suggestions or find something that seems wrong, please do not hesitate to contact us at curator@tbdreamdb.com
Saturday 01 October 2011

Exciting news at TBDreamDB! The Database is currently undergoing complete redesign and data evaluation. The database will be converted to a fully searchable relational Database with a new look front end website as well

We hope to have the beta design up and running towards the end of 2011 early 2012. Any feedback would be great, simply contact us at the curator email below.

Also please keep sending in any errors you find in the dataset. The data is being evaluated and corrected as it is being inserted into the new database format. -Your Emails are much appreciated!

Monday 12 April 2010

We have now released an updated version of the database encompassing all the novel mutations and frequency distribution data retreieved from papers published up to December 2009.

In this update we also provide links to TBDB and TubercuList for information about the individual genes. Finally, we also provide links to PubMed for the published papers from which the data have been retrieved.

Tuesday 23 June 2009
We have updated the rpoB pages to fix the bugs with displaying the High Confidence Mutations. Since we have received a lot of comments about the codon position numbering system of rpoB we have also decided to show the E.coli positions instead of the M.tuberculosis H37Rv positions. As before, you can find both E.coli and M.tuberculosis in the downloadable files below!
Inclusion criteria for new mutations
Friday 01 January 2010

We will include novel mutations found in clinical isolates of TB if they must fulfill the following criteria:

  1. They are from published studies of clinical M.tuberculosis isolates.
  2. They occur in isolates that have been characterized by phenotypic drug sensitivity testing.
  3. Mutations are identified by specification of the gene, nucleotide position and the nucleotide and/or amino acid change.
Inclusion criteria for new frequency data
Tuesday 28 January 2014

For studies to be included in the database describing the frequency of common mutations associated with drug resistance in M. tuberculosis, they must fulfill the following criteria:

  1. They must be studies of clinical M. tuberculosis isolates.
  2. They must have large sample sizes. Cut-offs for sample sizes for ETH, SM, FLQ and PZA have been determined empirically depending on the ten largest studies published so far.
    • Isoniazid: a minimum of 100 resistant isolates.
    • Rifampicin: a minimum of 100 resistant isolates.
    • Ethambutol: a minimum of 50 resistant isolates.
    • Streptomycin: a minimum of 36 resistant isolates.
    • Fluoroquinolones: a minimum of 35 resistant isolates.
    • Pyrazinamide: a minimum of 33 resistant isolates.
  3. They must report on phenotypic drug sensitivity testing for all isolates.
  4. They must use validated methods to identify drug resistance mutations.
  5. They must identify the nucleotide position and the nucleotide change.
  6. They must specify the number of resistant and sensitive isolates carrying a specific mutation.

© 2010 Andreas Sandgren  |  Supported by The Swedish Research Council  |  Contact Database Curator